Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has introduced its new qPCR Assay to the research community for virus detection and quantification, gene expression analysis, relative/absolute quantification, mutation analysis, and genotyping.
Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera.
Creative Diagnostics recently introduced the TCID50 Assay Service suitable for drug sensitivity tests, infectious units quantification, the determination of virus doses, as well as virus release studies.
Creative Diagnostics announced the launch of several mouse antibacterial monoclonal antibodies for the development of human and mouse anti-bacterial antibody detection kits.
Creative Diagnostics announced the launch of several mouse antibacterial monoclonal antibodies for the development of human and mouse anti-bacterial antibody detection kits.
Creative Diagnostics recently introduced Plaque Reduction Assay services to detect antibodies from testing serum and viruses within diseased materials to diagnose viral infectious diseases.
Creative Diagnostics recently introduced Hemagglutination Assay services for influenza vaccine, diagnostic, and surveillance communities to measure virus and antibody titers and monitor influenza subtypes.
Creative Diagnostics announced the launch of a panel of anti-PEG IgG or IgM ELISA kits with different species reactivity to detect anti-PEG IgG or IgM in serum and plasma.
Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA).
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics introduces a series of PEI PLGA Nanoparticles for gene delivery and gene therapy, which are based on poly(lactide-co-glycolide) acid terminated with a lactide/glycolide ratio of 50/50 and a molecular weight of 32000 Da. These nanoparticles are positively charged due to the surface modification with PEI.
Creative Diagnostics released two ELISA kits for qualitative detection of SARS-CoV-2 neutralizing antibody in serum and plasma to meet the demand of customers for vaccine development.
Satisfied Users & 
Approved Press Releases
